EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety

Qiang Li, Cunrui Li, Yuanmin Chang, Mingzhi Su, Rilei Yu iD, Zhangjian Huang iD, Yue-Wei Guo iD, Xin Jin

Journal of Medicinal Chemistry · 22.05.2025 · 68 (10) · 10008-10030

DOI: 10.1021/acs.jmedchem.4c03047 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 08.05.2025. Verfasst von Qiang Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China. Hauptthemen laut MEDLINE: rho-Associated Kinases, Glaucoma, Protein Kinase Inhibitors, Drug Design. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Natural Science Foundation of Shandong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The inhibition of Rho-associated coiled-coil kinase (ROCK) has emerged as a promising strategy for reducing intraocular pressure (IOP) and treating glaucoma. Here, we report the synthesis and evaluation of novel ROCK inhibitors, D25 and R3, which were designed to optimize selectivity, efficacy, and ocular bioavailability. D25 potently inhibited ROCK1/2 with IC50 values of 47.2 nM and 33.8 nM, respectively, surpassing Netarsudil. Compound R3 had weaker ROCK inhibition but demonstrated favorable lipophilicity (logP) and good selectivity to ROCKs, which enhances its potential and safety for ocular delivery. In human trabecular meshwork (HTM) cells, R3 showed lower cytotoxicity than Netarsudil and effectively mitigated oxidative damage, enhanced cellular integrity, and reduced inflammatory cytokine secretion. In rabbit models, D25 significantly lowered IOP, outperforming (S)-Netarsudil. R3 exhibited weaker IOP-lowering efficacy but better selectivity. D25 is a promising glaucoma treatment candidate, with R3 as a safer alternative for further optimization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

rho-Associated KinasesGlaucomaProtein Kinase InhibitorsDrug DesignAnimalsHumansRabbitsIntraocular PressureStructure-Activity RelationshipTrabecular MeshworkMale

Substanzen

rho-Associated KinasesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250117, China.
  • Shandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
  • State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Drug Discovery for Metabolic Diseases, Center of Drug Discovery, China Pharmaceutical University, Nanjing 210009, China.
  • School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
  • School of Medicine, Shanghai University, Shanghai 200444, China.

ORCID-Profile: Rilei Yu, Zhangjian Huang, Yue-Wei Guo

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Natural Science Foundation of Shandong Province
  • Key Technology Research and Development Program of Shandong Province
  • Shandong Laboratory Program

Zitieren

APA

Li, Q., Li, C., Chang, Y., Su, M., Yu, R., Huang, Z., Guo, Y. W., & Jin, X. (2025). Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety. Journal of Medicinal Chemistry, 68(10), 10008-10030. https://doi.org/10.1021/acs.jmedchem.4c03047

Vancouver

Li Q, Li C, Chang Y, Su M, Yu R, Huang Z, et al. Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety. Journal of Medicinal Chemistry. 2025;68(10):10008-10030. doi:10.1021/acs.jmedchem.4c03047

BibTeX
@article{Li2025,
  author = {Li, Qiang and Li, Cunrui and Chang, Yuanmin and Su, Mingzhi and Yu, Rilei and Huang, Zhangjian and Guo, Yue-Wei and Jin, Xin},
  title = {Design, Synthesis, and Evaluation of Novel ROCK Inhibitors for Glaucoma Treatment: Insights into In Vitro and In Vivo Efficacy and Safety},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {10},
  pages = {10008--10030},
  doi = {10.1021/acs.jmedchem.4c03047}
}
Kostenlos starten →